UBS (UBS) released estimates for its second-quarter results on Monday in an apparent effort to pre-signal the markets about its actual results, which are set to be released July 30.
The global investment bank expects its operating profit before taxes to be up 7% from last year to roughly 1.020 billion Swiss francs (or $1.3 billion) and its net profit attributable to shareholders to jump 62% to about 690 million Swiss francs ($742 million).
Last year, it reported a second-quarter operating profit before taxes of 951 million Swiss francs ($1.02 billion) and a net profit of 425 million Swiss francs ($457 million).
The bank also says that its Basel III common equity tier 1 ratio should “improve significantly to approximately 11.2% on a fully applied basis and 16.2% on a phase-in basis.”
These preliminary results include pre-tax charges of about 865 million Swiss francs (or $930 million) for litigation, other provisions and an impairment of financial assets; some 700 million Swiss francs ($753 million) is expected to affect the results of the Corporate Center, while roughly CHF 100 million ($108 million) will impact its non-U.S. Wealth Management in relation to the Swiss-U.K. tax agreement.
10 Best Heal Care Stocks To Buy For 2014: Rambler Metals And Mining Plc(RAB.V)
Rambler Metals & Mining PLC, a junior mining company, engages in the exploration and development of mineral properties in Canada. It principally holds a 100% interest in the Ming copper-gold mine located on Newfoundland and Labrador?s Baie Verte Peninsula. The company is based in Sutton, the United Kingdom.
10 Best Heal Care Stocks To Buy For 2014: Xyratex Ltd.(XRTX)
Xyratex Ltd provides modular solutions for the enterprise data storage industry and hard disk drive (HDD) capital equipment for the HDD industry. It offers enterprise data storage solutions that include storage enclosures, which provide a common technology platform that reduces qualification time for original equipment manufacturer (OEM) customers and includes management interface software, standardized across enclosures, and provides easy integration as new platforms; integrated application platforms that comprise embedded storage platforms, which incorporate embedded server modules into its storage enclosures; and HPC Solutions that consolidate controllers, storage enclosures, application platforms, operating system, data protection, Lustre File System, and management software into a optimized scale-out storage platform that can be deployed in hours rather than weeks. The company also designs and manufactures a range of process test systems, which incorporate mechanical and electronic hardware, and firmware for controlling the HDD operating environment during the formatting of the disk drive. In addition, it provides automated solutions comprising substrate and media inspection systems; servo track writers and related subassemblies; and head testing systems that test and process HDD components throughout the manufacturing process. The company markets and sells its products primarily to OEMs and disk drive manufacturers, as well as to other companies in North America, Asia, and Europe. Xyratex Ltd was founded in 1966 and is headquartered in Havant, the United Kingdom.
Advisors' Opinion:- [By Monica Gerson]
Xyratex (NASDAQ: XRTX) reported a drop in its third-quarter profit. However, the company issued downbeat forecast for the fourth quarter. Xyratex shares tumbled 7.83% to $11.06 in the after-hours trading session.
Top Stocks To Watch Right Now: SkyPeople Fruit Juice Inc.(SPU)
SkyPeople Fruit Juice, Inc., through its subsidiaries, engages in the production and sale of fruit juice concentrates, fruit beverages, and other fruit related products in the People?s Republic of China. It offers fruit concentrates, such as fruit purees, concentrated fruit purees, and concentrated apple, pear, and kiwifruit juices; fruit juice and fruit cider beverages that include apple juice, pear juice, kiwifruit juice, mulberry juice, kiwifruit cider, and mulberry cider; and other fruit related products, such as organic and non-organic fresh fruits, fresh vegetables, dried fruits, preserved fruits, fructose, concentrated turnjujube juice, kiwifruit seeds, and apple spice. The company sells its products directly to hotels, supermarkets, whole sellers, and other outlets, as well as to end-users; and through distributors and trade Web sites. SkyPeople Fruit Juice, Inc. also exports its products to the United States, the European Union, South Korea, Russia, and the Middl e East. The company is headquartered in Xi?an, the People?s Republic of China.
10 Best Heal Care Stocks To Buy For 2014: Affirmative Insurance Holdings Inc.(AFFM)
Affirmative Insurance Holdings, Inc., through its subsidiaries, operates as a distributor and producer of non-standard personal automobile insurance policies and related products and services for individual consumers in the United States. It offers liability-only policies that comprise bodily injury liability coverage, property damage liability coverage, and personal injury protection coverage and/or medical payment coverage. The company also provides full coverage policies, which include collision coverage for damage to the insured vehicle as a result of a collision with another vehicle or object; comprehensive coverage for damages to the insured vehicle as a result of theft, hail, and vandalism; and optional coverages, such as towing, rental reimbursement, and special equipment. In addition, Affirmative Insurance Holdings, Inc. sells third-party non-standard personal automobile insurance policies; and complementary insurance products underwritten by third-party insurance companies, including homeowners and renters insurance, motorcycle and recreational vehicle coverage, vehicle protection, and travel protection; and non-insurance products and services, which comprise towing, motor club memberships, hospital indemnity insurance, and bond cards. Affirmative Insurance Holdings, Inc. distributes its products through independent agencies, unaffiliated underwriting agencies, and retail agencies, as well as through premium finance companies. The company was formerly known as Instant Insurance Holdings, Inc. Affirmative Insurance Holdings, Inc. was founded in 1998 and is based in Addison, Texas.
10 Best Heal Care Stocks To Buy For 2014: Yangaroo Inc(YOO.V)
Yangaroo Inc., a technology company, enables secure business to business distribution of media via the Internet. It offers digital media distribution system (DMDS), a Web-based delivery system that enables secure digital file distribution by incorporating biometrics, encryption, and watermarking. The company?s DMDS replaces the physical distribution of audio and video content for music, music videos, and advertising to television, radio, media, retailers, award shows, and other authorized recipients with digital delivery of broadcast quality media through the Internet. It offers DMDS Music that delivers new music to broadcasters, radio programmers, journalists, and other industry influencers; and DMDS Advertising, which delivers audio and video files to broadcasters. Yangaroo Inc. serves music and advertising industries. The company was formerly known as Musicrypt.com Inc. and changed its name to Yangaroo Inc. in July 2007. Yangaroo Inc. was founded in 1999 and is headqua rtered in Toronto, Canada.
10 Best Heal Care Stocks To Buy For 2014: Fuwei Films(Holdings)
Fuwei Films (Holdings) Co., Ltd., together with its subsidiaries, engages in the development, manufacture, distribution, and export of plastic film using the biaxially-oriented stretch technique in China. The company offers its biaxially oriented polyethylene terephthalate (BOPET) film under the ?Fuwei Films? brand name primarily for use in flexible packaging, printing, laminating, and aluminum-plating applications, as well as in electrical and electronic uses. Its products include printing base film used in printing and lamination applications; stamping foil base film and transfer base films used for the packaging of luxury items, such as cigarettes and alcohol; metallization film or aluminum plating base film used for vacuum aluminum plating for flexible plastic lamination; high-gloss film used for aesthetically enhanced packaging purposes; and heat-sealable film used for construction, printing, and heat sealable bags making. The company?s products also comprise laser holographic base film used as anti-counterfeit film for food, medicine, cosmetics, cigarettes, and alcohol packaging; dry film used in circuit boards production, and for nameplate and crafts etching; and heat shrinkage film used for special-shaped packaging for alcohol, cans, mineral water, and cleaning products. It exports its products to packaging customers and distributors primarily in Europe, Asia, and North America. The company was founded in 2003 and is headquartered in Weifang, China. As of May 1, 2011, Fuwei Films (Holdings) Co., Ltd. operates as a subsidiary of Weifang State-owned Assets Operation Administration Company.
Advisors' Opinion:- [By Adam Haigh]
Among stocks that fell, Yue Yuen Industrial (Holdings) Ltd. (551), a supplier of shoes to Nike Inc. and Adidas AG, sank 12 percent to HK$23.80. The company said its first-quarter results showed a ��ignificant downturn��compared with a year earlier and this could adversely affect interim performance.
10 Best Heal Care Stocks To Buy For 2014: Sarepta Therapeutics Inc (SRPT.W)
Sarepta Therapeutics Inc., formerly AVI BioPharma, Inc., incorporated on July 22, 1980, biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of rare and infectious diseases. The Company�� product candidates include Eteplirsen, AVI-6002, AVI-6003, and AVI-7100. As of December 31, 2011, the Company primarily focused on advancing the development of its Duchenne muscular dystrophy drug candidates, including its lead product candidate, eteplirsen, which is in a Phase IIb trial. The Company is also focused on developing therapeutics for the treatment of infectious diseases, including its lead infectious disease programs aimed at the development of drug candidates for the Ebola and Marburg hemorrhagic fever viruses. The Company's program focuses on the development of disease-modifying therapeutic candidates for Duchenne muscular dystrophy (DMD). The Company initiated a Phase IIb trial for eteplirsen in August 2011 with an objective of initiating a pivotal trial subsequent to 2011.
The Company is also leveraging the capabilities of its RNA-based technology platforms to develop therapeutics for the treatment of infectious diseases. The Company's RNA-based drug programs are clinically evaluated for the treatment of DMD and have also demonstrated anti-viral activity in infectious diseases such as Ebola, Marburg and H1N1 influenza in certain animal models. The Company's lead product candidates are at various stages of development.
Duchenne Muscular Dystrophy Program
The Company's lead program is designed to address specific gene mutations that result in DMD by forcing the genetic machinery to skip over an adjacent contiguous piece of RNA and, thus, restore the ability of the cell to express a new, truncated but functional, dystrophin protein.
Eteplirsen is an antisense PMO-based therapeutic in clinical development for the treat ment of individuals with DMD who have an error in the gene ! c! oding for dystrophin that can be treated by skipping exon 51. Eteplirsen targets the frequent series of mutations that cause DMD. Eteplirsen has been granted orphan drug designation in the United States and European Union. In addition to the Company's lead product candidate, eteplirsen, the Company is actively pursues development of a product candidate that skips exon 45 through an IND-enabling collaboration.
Anti-Viral Programs
The Company is implementing its RNA-based technology platforms in its anti-viral programs for the development of therapeutics to treat viruses, such as Ebola, Marburg and influenza. The Company's arrangement with DoD supporting the development of the Company's Ebola and Marburg virus drug candidates provides funding for all clinical and licensure activities necessary to obtain approval of a New Drug Application (NDA), by the United States Food and Drug Administration (FDA), if DoD exercises all of its options under the arra ngement. During the year ended December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and is exploring funding opportunities or partnerships with DHHS and industry collaborators to advance its development.
The Company's anti-viral therapeutic programs use the Company's translation suppression technology and applies its PMOplus chemistry backbone, an advanced generation of its base PMO chemistry backbone that selectively introduces positive backbone charges to improve selective interaction between the drug and its target. The Company's translation suppressing technology is based on Translation Suppressing Oligomers (TSOs), which are PMO-based compounds that stop or suppress the translation of a specific protein by binding to their specific target sequence in mRNA.
The Company is pursuing development and regulatory approval of its Ebola and Marburg hemorrhagic fever virus product candidates under the FDA's Animal Rule. The Company's lead product candidate against the Ebola viru! s in! fec! tion i! s AVI-6002. For Marburg virus infection, the Company's lead product candidate has been AVI-6003. In February 2012, the Company announced that the Company received approval from the FDA to remove one of the two oligomers composing AVI-6003 and proceed with a single oligomer approach, AVI-7288, given that efficacy in non-human primates has been demonstrated to be attributable to this single oligomer. The Company is exploring the feasibility of alternate routes of administration of its Ebola and Marburg drug candidates, and at DoD's invitation, the Company is developing a proposal to be submitted for a study to demonstrates feasibility of the intramuscular route.
AVI-6002, which is a combination of AVI-7537 and AVI-7539, is designed for post-exposure prophylaxis after documented or suspected exposure to the Ebola virus. The Company is evaluating the feasibility of developing AVI-7537 as a single agent for the post-exposure prophylaxis after documented or suspected exposure to Ebola virus. AVI-6003, which is a combination of AVI-7287 and AVI-7288, is designed for post-exposure prophylaxis after documented or suspected exposure to Marburg virus. In February 2012, the Company announced that the Company received approval from the FDA to proceed with AVI-7288 as a single agent against Marburg virus infection. The Company intends to proceed with dosing AVI-7288 in the Phase I multiple ascending dose studies and in non-human primate studies.
Influenza Program
The Company's anti-viral therapeutic programs are also focused on the development of the Company's product candidates designed to treat pandemic influenza viruses. AVI-7100 is the Company's lead product candidate for the treatment of influenza and employs its PMOplus technology. In June 2011, the Company initiated dosing of AVI-7100 through intravenous infusion in single-ascending doses in up to 48 healthy adult volunteers. As of December 31, 2011, the Company paused its clinical development efforts on AVI-7100 ! and are !! exploring! funding opportunities or partnerships to advance its development.
The Company has developed three new phosphorodiamidate-linked morpholino oligomers (PMO)-based chemistry platforms in addition to its original PMO-based technology. The Company's PMO-based molecules are designed to sterically block the access of cellular machinery to pre-mRNA and mRNA without degrading the RNA. Through this selective targeting, two distinct biologic mechanisms of action can be initiated: modulation of pre-mRNA splicing and inhibition of mRNA translation.
The Company competes with GlaxoSmithKline plc, Toyama Chemical, Alnylam Pharmaceuticals, Inc., Tekmira Pharmaceuticals Corp., Isis Pharmaceuticals, Inc., Prosensa, and Santaris Pharma A/S.
10 Best Heal Care Stocks To Buy For 2014: Falcon Oil & Gas Ltd (FO)
Falcon Oil & Gas Ltd. (Falcon) is an energy company engaged in the business of acquiring, exploring and developing petroleum and natural gas properties. The Company focuses on the acquisition, exploration and development of conventional and unconventional petroleum and natural gas projects in Central Europe (specifically Hungary), Australia and South Africa. Falcon holds 100% interest in 245,775 acres in a production license in the Mako Trough, southern Pannonian Basin in Hungary. Effective July 18, 2013, Falcon Oil & Gas Ltd raised its interest to 96.9% from 72.68%, by acquiring a further 24.22% interest in Falcon Oil & Gas Australia Ltd, from Sweetpea Petroleum Corp Pty Ltd, a unit of PetroHunter Energy Corp. Effective September 19, 2013, Falcon Oil & Gas Ltd acquired the remaining 3.1% stake, which it did not already own, in Falcon Oil & Gas Australia Ltd, a oil and gas exploration and production company.10 Best Heal Care Stocks To Buy For 2014: PFSweb Inc.(PFSW)
PFSweb, Inc. provides business process outsourcing and ecommerce solutions in the United States, Canada, and Europe. It offers digital marketing services comprising search engine optimization, pay-per-click, affiliate marketing, comparison shopping engines, merchandising, Web analytics, customer experience, email marketing, and social media; and ecommerce technology services, including End2End eCommerce solution for the direct-to-consumer (DTC) and business-to-business (B2B) online channels. The company also provides order management services consisting of order management interfaces, collaboration technologies, and information management services; customer care services, including customer relationship management, customer order assistance, quality monitoring, and interactive voice response; and logistics and fulfillment services comprising distribution facilities and infrastructure, facility operations and management, kitting and assembly, and product management and insp ection. In addition, it offers financial management services consisting of billing, credit, collection, and cash application services for B2B clients, as well as fraud review, chargeback management, and processing and settlement credit card services for DTC clients; and professional consulting services in the areas of interactive marketing ecommerce, supply chain management, distribution and fulfillment, technology interfacing, logistics, and customer support. Further, the company provides seller services financial models, including enablement financial, agent or flash financial, and retail financial models. It serves fashion apparel and accessories, fragrance and beauty products, consumer packaged goods, home furnishings and housewares, consumer electronics, office technology and network connectivity products, and aviation spare parts industries. The company was founded in 1999 and is headquartered in Allen, Texas.
10 Best Heal Care Stocks To Buy For 2014: Align Technology Inc.(ALGN)
Align Technology, Inc., a medical device company, designs, manufactures, and markets clear aligner systems or Invisalign systems, intra-oral scanners, and computer-aided design (CAD) and computer-aided manufacturing (CAM) restorative models used in dentistry, orthodontics, and dental records storage in North America and Internationally. The company?s clear aligner products include Invisalign Full for the treatment of malocclusions; Invisalign Express and Invisalign Lite solutions for less complex orthodontic cases; Invisalign Teen, which is primarily marketed to orthodontists for treating malocclusion in teenage patients; Invisalign Assist for use in anterior alignment and aesthetically-oriented cases; and Vivera retainers for invisalign and non-invisalign patients. It also offers ancillary products comprising cleaning material and adjusting tools used by dental professionals during the course of treatment. In addition, the company provides iTero scanners; iOC scanners; a nd iTero dual scanner, which includes both the iTero restorative software and the iOC orthodontic software, as well as services comprising iTero restorative and OrthoCAD services. Further, it offers CAD/CAM services, such as iTero Models and Dies; OrthoCAD iCast and OrthoCAD iRecord that provides a digital alternative to traditional stone cast models, which allows for simplified storage and digital record retrieval; and OrthoCAD iQ, a computer-guided system for optimal placement of traditional brackets and customized indirect bonding tray system. The company distributes its products primarily directly to orthodontists and general practitioner dentists, as well as restorative dentists, including prosthodontists, periodontists, and oral surgeons. Align Technology, Inc. was founded in 1997 and is headquartered in San Jose, California.
Advisors' Opinion:- [By Sean Williams]
What: Shares of Align Technology (NASDAQ: ALGN ) , a medical device and software design company for the dental and orthodontics industry, jumped as much as 12% after reporting better-than-expected second-quarter results.
- [By Ben Levisohn]
Its braces might be invisible but Align Technology’s (ALGN) gains are not.
Getty ImagesThe maker of transparent braces and other dental products reported earnings of 42 cents a share, week above analyst forecasts for a 30 cent profit. Revenue, meanwhile, rose to $164.5 million, above the $158.6 million forecast.
William Blair’s John Kreger and team are impressed:
We are encouraged by the strong results, which stand in stark contrast to second half 2012 when volume growth and margins declined unexpectedly. Align’s Invisalign is clearly gaining market share, generating 16% unit growth in an environment where overall orthodontic procedures are essentially flat by our estimates.
Stifel’s Jonathan Block and Ethan Roth can barely contain their excitement. They write:
Our entire 2014 leverage thesis played out in 3Q13 as ALGN significantly beat EPS numbers…yet we were silly enough to make a cautious call in front of the quarter. That said, we think our 2014 $1.66 versus the Street�� $1.53 should no longer be viewed as an ��nrealistic expectation��and we believe consensus likely brings their estimates up to us��overnight. Align seems to be in the sweet spot as past investments (APAC, N.A. sales reps) are starting to pay off and new innovations (SmartTrack) are resonating with docs and helping to drive utilization higher. We are raising our 2014 and 2015 EPS estimates. Reiterate Buy and increase PT from $54 to $57.
Cantor Fitzgerald’s Jeremy Feffer upgrades Aligns shares to Buy from Hold:
After seemingly hitting bottom in 3Q:12, ALGN has taken concrete steps to revitalize its North American GP dentist segment, stabilize/improve pricing, and build a formidable O-U.S. sales and training operation, all of which are paying dividends. With better overall volume trends, the ClearCorrect ITC victory, and the Realine launch, we see plenty of runway for continued outperformance.
- [By Keith Speights]
Bracing for success
Preliminary third-quarter results sent shares of orthodontic medical device maker Align Technology (NASDAQ: ALGN ) soaring by nearly 34% this week. Align blew past expectations on both the top and bottom lines.